Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBlue Cross Blue Shield Nebraska Harliku Prior Auth…
    Ask Trek AI about this page
    DraftBlue Cross Blue Shield - NebraskaPolicy N/A

    HARLIKU (nitisinone) — Preauthorization Required

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Nebraska policy alerts

    Know when Blue Cross Blue Shield - Nebraska releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Preauthorization policy governing medical necessity criteria for Harliku (nitisinone) to reduce urinary homogentisic acid (HGA) in patients with alkaptonuria; applies to coverage decisions made by Blue Cross Blue Shield - Nebraska.

    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyHARLIKU (nitisinone) — Preauthorization Required
    Policy CodePolicy N/A
    Change TypeNo material change (draft)
    Effective DateJul 1, 2026
    Next Review DateNov 4, 2026
    Key ActionSubmit prior authorization with diagnosis of alkaptonuria and 24-hour urine HGA ≥1 g, plus required documentation and specialist involvement.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    88-91%reported HGA reduction
    >=1 g/dayHGA threshold
    2 mgstudied dose
    07-01-2026effective date

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Harliku (nitisinone)

    Initial therapy criteria

    Covered when ALL of the following are met

    Initial Evaluation: I. The patient has a diagnosis of alkaptonuria

    chunk 8

    Urine HGA: II. 24-hour urine homogentisic acid (HGA) >= 1 gram (medical records required)>= 1 g/24 hr

    chunk 8

    Age/Indication: III. If the patient has an FDA labeled indication, then ONE of: A) The patient’s age is within FDA labeling for the requested indication OR B) There is support for using the requested agent for the patient’s age for the requested indication

    chunk 8

    Prior agent therapy: IV. ONE of: A) Tried and had an inadequate response to TWO prerequisite agents (e.g., nitisinone capsule, Nityr tablet) that is NOT expected to occur with the requested agent; OR B) Tried and had an inadequate response to ONE prerequisite agent AND an intolerance or hypersensitivity to ONE prerequisite agent that is NOT expected to occur with the requested agent; OR C) An intolerance or hypersensitivity to TWO prerequisite agents that is NOT expected to occur with the requested agent; OR D) An FDA labeled contraindication to ALL prerequisite agents that is NOT expected to occur with the requested agent

    chunk 8

    Specialist involvement: V. The prescriber is a specialist in the area of the patient’s diagnosis (e.g., geneticist, rheumatologist) or the prescriber has consulted with a specialist in the area of the patient’s diagnosis

    chunk 8

    Contraindications: VI. The patient does NOT have any FDA labeled contraindications to the requested agent

    chunk 8

    Quantity/Dose limits: VII. The requested quantity (dose) does NOT exceed the program quantity limit OR VIII. The requested quantity (dose) exceeds the program quantity limit AND ONE of the following: A) BOTH: 1) The requested agent does NOT have a maximum FDA labeled dose for the requested indication AND 2) There is support for therapy with a higher dose for the requested indication; OR B) BOTH: 1) The requested quantity (dose) does NOT exceed the maximum FDA labeled dose for the requested indication AND 2) There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does NOT exceed the program quantity limit

    chunk 8, chunk 9

    Renewal criteria

    Renewal Evaluation covered when ALL of the following are met

    Prior approval: I. The patient has been previously approved for the requested agent through the plan's Prior Authorization process

    chunk 9

    Clinical benefit: II. The patient has had clinical benefit with the requested agent as indicated by a reduction in urinary homogentisic acid (medical records required)reduction in urinary HGA

    chunk 9

    Specialist involvement (renewal): III. The prescriber is a specialist in the area of the patient’s diagnosis (e.g., geneticist, rheumatologist), or the prescriber has consulted with a specialist in the area of the patient’s diagnosis

    chunk 9

    Contraindications (renewal):

    No FDA-labeled contraindications specific to Harliku were identified in this policy, and the policy states that Harliku does not carry any black box warnings.

    Patients who do not meet all elements of the Initial Evaluation criteria described in this policy are not considered to meet medical necessity. Examples include: lacking a documented diagnosis of alkaptonuria, having a 24-hour urine homogentisic acid (HGA) measurement that is below the required threshold of >= 1 gram, failing to meet the prerequisite agent requirements (trials, inadequate response, or documented intolerance/hypersensitivity), absence of specialist involvement or consultation, presence of FDA-labeled contraindications to the requested agent, or requests for doses that exceed program limits without required justification.

    Key Coding and Test Thresholds

    inv-05: 24-hour urine HGA — numeric threshold required for initial approval
    Numeric threshold for initial approval24-hour urine homogentisic acid (HGA) >= 1 gram (medical records required)
    Sample collection methodMeasured from a 24-hour urine sample
    Documentation requirementMedical records must include the 24-hour urine HGA measurement to support initial authorization
    Use in decision-makingA value below 1 g/24 hr does not meet the policy’s initial evaluation threshold

    Provider Requirements and Authorization Actions

    Prior Authorization

    Preauthorization required for Harliku — initial approval conditions

    Prior authorization is required for Harliku (nitisinone). Initial approval requires a diagnosis of alkaptonuria and a 24‑hour urine HGA ≥ 1 gram, meeting FDA age labeling or providing clinical justification for use outside FDA age limits, specialist prescriber or documented specialist consultation, absence of any FDA‑labeled contraindications to the requested agent, and dosing within program quantity limits or meeting the program’s exception criteria for higher doses.

    • Diagnosis of alkaptonuria is required (Initial Evaluation I).
    • 24‑hour urine HGA ≥ 1 gram (Initial Evaluation II; medical records required).
    • If the patient has an FDA‑labeled indication, patient age must be within FDA labeling or there must be support for use in that age (Initial Evaluation III).
    • Prescriber must be a specialist or have consulted with a specialist (Initial Evaluation V).
    • Patient must not have any FDA‑labeled contraindications to the requested agent (Initial Evaluation VI).
    • Requested quantity/dose must not exceed program limits or must meet the program’s criteria for exceeding limits (Initial Evaluation VII/VIII and chunk 9).
    Step Therapy

    Prerequisite agent trials and intolerance/contraindication requirements

    Prior therapy/prerequisite requirements must be documented: the patient must meet ONE of the listed step‑therapy scenarios showing trial and inadequate response or intolerance/contraindication to prerequisite agents (examples given: nitisinone capsule, Nityr tablet).

    • Option A: Tried and had inadequate response to TWO prerequisite agents (e.g., nitisinone capsule, Nityr tablet) not expected with the requested agent.
    • Option B: Tried and had inadequate response to ONE prerequisite agent AND intolerance/hypersensitivity to ONE prerequisite agent not expected with the requested agent.
    • Option C: Intolerance/hypersensitivity to TWO prerequisite agents not expected with the requested agent.
    • Option D: FDA‑labeled contraindication to ALL prerequisite agents not expected with the requested agent.
    Documentation Required

    Required medical records and prior‑approval documentation

    Medical records must contain specific documentation for initial and renewal review: a 24‑hour urine HGA measurement of ≥ 1 gram for initial approval and documentation of reduction in urinary HGA for renewals; specialist consultation notes if the prescriber is not a specialist; and prior authorization approval record for renewals.

    • Initial: 24‑hour urine homogentisic acid (HGA) ≥ 1 gram (medical records required).
    • Renewal: documentation of reduction in urinary HGA demonstrating clinical benefit (medical records required).
    • Specialist involvement: consultation notes if prescriber is not a specialist (Initial Evaluation V; Renewal III).
    • Renewal: evidence the patient was previously approved through the plan’s Prior Authorization process (Renewal I).
    Denial Risk

    Denial risks if required diagnosis, HGA, or documentation are missing

    Requests risk denial when required criteria or documentation are missing: lack of a diagnosis of alkaptonuria, 24‑hour urine HGA < 1 gram/24 hr, missing prior authorization record for renewals, absent specialist involvement or consultation, presence of FDA‑labeled contraindications to the requested agent, or requested dose/quantity exceeding program limits without meeting the exception criteria.

    • No documented diagnosis of alkaptonuria (Initial Evaluation I).
    • 24‑hour urine HGA less than 1 gram/24 hours or missing urine HGA result (Initial Evaluation II).
    • For renewals, lack of prior approval through the plan’s Prior Authorization process or missing documentation of reduction in urinary HGA (Renewal I–II).
    • Prescriber is not a specialist and no documented specialist consultation (Initial V; Renewal III).
    • Documented FDA‑labeled contraindication to the requested agent (Initial VI; Renewal IV).
    • Requested quantity/dose exceeds program limits without meeting the program’s higher‑dose support criteria (Initial VII/VIII and chunk 9).

    Background on Alkaptonuria and Nitisinone

    Alkaptonuria (AKU) is an inherited metabolic disorder characterized by accumulation of homogentisic acid (HGA) due to defects in tyrosine catabolism. Elevated urinary HGA leads to progressive tissue deposition (ochronosis) and related clinical manifestations. Nitisinone (Harliku) inhibits 4-hydroxyphenylpyruvate dioxygenase in the tyrosine degradation pathway and has been shown to markedly reduce urinary HGA levels in treated patients. Clinical data cited in the policy report large reductions in urinary HGA and symptom improvement for some patients treated with nitisinone.

    Definitions and Biomarkers

    inv-11: Homogentisic acid (HGA) — the metabolite measured in 24-hour urine collections to assess disease activity and treatment response in AKU.
    DefinitionHomogentisic acid (HGA) is the metabolite measured in 24-hour urine collections to assess disease activity and treatment response in alkaptonuria (AKU).
    Clinical roleHGA levels reflect disease activity and are used to evaluate response to nitisinone therapy (Harliku), which markedly reduces urinary HGA.
    Measurement timingTypically assessed using a 24-hour urine collection; reductions are evaluated on follow-up testing to document clinical benefit for renewals.
    Therapeutic relevanceNitisinone (Harliku) has been shown to produce large reductions in urinary HGA (e.g., ~88–91% reduction at 1–3 years in clinical studies).
    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyHARLIKU (nitisinone) — Preauthorization Required
    Policy CodePolicy N/A
    Change TypeNo material change (draft)
    Effective DateJul 1, 2026
    Next Review DateNov 4, 2026
    Key ActionSubmit prior authorization with diagnosis of alkaptonuria and 24-hour urine HGA ≥1 g, plus required documentation and specialist involvement.
    SourceLink
    On This Page
    Coverage Criteria for Harliku (nitisinone)Key Coding and Test ThresholdsProvider Requirements and Authorization ActionsBackground on Alkaptonuria and NitisinoneDefinitions and Biomarkers
    IV. The patient does NOT have any FDA labeled contraindications to the requested agent

    chunk 9